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Abstract 
 
The studies described in this dissertation focus on metabolic adaptations that 
occur during cell proliferation. In the first part of the thesis we focus on the Warburg 
effect which is a major hallmark of proliferating cells. We provide evidence that 
increased glucose consumption in proliferating cells requires malate 
dehydrogenase 1 (MDH1) to help regenerate the NAD required to sustain high 
levels of glycolysis. This NAD regeneration has previously only been attributed to 
lactate dehydrogenase (LDH). We found LDH was dispensable for proliferation 
whereas MDH1 was not. We also report the MDH1 gene is amplified in a significant 
number of human tumors and correlates with poor prognosis. We go on to show 
glutamine, not glucose is a carbon source for MDH1 during proliferation, which 
allows more of the glucose carbon consumed to go toward biomass production. 
The second part of the thesis focuses on glutamine metabolism. The increased 
consumption and metabolism of glutamine leads to increased cellular 
concentrations of alpha-ketoglutarate (αKG) a tumor suppressor metabolite that 
affects gene expression via non-metabolic co-factor functions. One of these 
functions is the activation of the cytosine demethylase, Tet. Increased αKG 
concentrations therefore change the tumor cell’s epigenetic landscape which can 
cause differentiation and growth arrest. We reasoned cancer cells must have 
mechanisms in place to prevent the tumor suppressor activity of αKG. We 
demonstrate that over-expression of the one carbon metabolism pathway which 
generates methyl groups and the cytosine methyl-transferase, DNMT1 provide an 
αKG resistance mechanism. We find combining αKG treatment with low 
concentrations of the DNMT1 inhibitor decitabine causes significant cell death and 
reveals a potential therapeutic vulnerability in glutamine addicted cancers. Taken 
together, our studies provide significant insight into the general biology of 
proliferative metabolism. Through these insights, our work opens new avenues for 
targeting the energy and biomass producing pathways cancer cells depend on to 
proliferate. 
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Chapter 1 
Introduction 
 
	 	
	 2 
Switching from a quiescent to a proliferative state requires a cell to significantly 
alter its consumption and disbursement of resources. Cellular proliferation entails 
controlled allocation of carbons to a variety of anabolic pathways, and cancer cells 
have exploited and reprogrammed these pathways to sustain prolonged 
proliferation. Otto Warburg had observed, nearly a century ago, that solid tumors 
increased their glucose consumption and lactate production(Warburg et al., 1927). 
These seminal observations have withstood the test of time and, although our 
understanding of the pathways cancer cells use to support their need to grow is 
much broader and deeper, even today increased glucose consumption and lactate 
production are universally accepted as hallmarks of proliferative metabolism. 
While Warburg’s hypothesis could explain the rapid uptake and (albeit inefficient) 
metabolism of glucose as a means for meeting the energy demands of cell growth 
and division, it could not explain how cells were able to continue to grow and 
proliferate. Meanwhile, reports of proliferating cells utilizing glucose carbons for 
biomass production were beginning to emerge, creating a conundrum. 
 
Once the cell cycle is initiated, several metabolic pathways are altered to prepare 
the cell for division (Figure 1-1). For example, the Pentose Phosphate Pathway 
(PPP) usurps some glucose carbon early in the glycolytic process for production 
of ribose-5 phosphate, the backbone for nucleotides needed for DNA synthesis. In 
addition, the PPP generates 2 molecules of NADPH, a key reductive molecule that 
protects cells from increased reactive oxygen species (ROS) and a necessary co-
factor for de novo lipid synthesis (Lunt and Vander Heiden, 2011).  
As glucose carbon progresses through glycolysis it is also diverted, as 
dihydroxyacetone phosphate (DHAP), to supply the cell with glycerol 3-phosphate, 
the phospholipid cap needed for the synthesis of cell membrane (Lunt and Vander 
Heiden, 2011).  
 
Later in glycolysis, 3-phosphoglycerate is used for the synthesis of serine, glycine 
and cysteine which, besides serving as important amino acids and amino acid  
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Figure 1-1. Glucose carbon handling during quiescence and proliferation. 
Schematic depiction of glycolysis during proliferation (left) and re-redirection of glucose 
carbon for biomass production and redox control during proliferation (right).  
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precursors, are also starting points for macromolecular synthesis through the 
tetrahydrofolate (THF) and ceramide (cholesterol) pathways used for membrane 
synthesis and nucleotides respectively (Lunt and Vander Heiden, 2011). 
 
The Warburg Effect  
The demand for biomass production during proliferation is high; therefore, it is not 
surprising that glucose consumption increases to meet this demand. Otto Warburg 
observed the increased glucose consumption in proliferating tumor cells in the 
Figure 1-2. The NAD/NADH cycle in glycolysis. NAD utilized by GAPDH is thought to 
be regenerated by lactate dehydrogenase (LDH) in traditional Warburg models. However, 
glucose carbon is directed away from glycolysis to generate biomass (red). Given the 
reduction in glucose carbon supplied to LDH we predict there must be some alternative 
reaction that supports NAD regeneration in the cytosol. 
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early part of the twentieth century (reviewed in (Koppenol et al., 2011; Vander 
Heiden et al., 2009). Warburg also observed that these cells secreted an unusually 
high amount of acid in tandem with the increased glucose consumption (Warburg 
et al., 1927). The “Warburg Effect” postulates that glucose carbon is rapidly 
processed through glycolysis to lactate in the cytosol, precluding its participation 
in the TCA. Since glycolysis on its own produces two molecules of ATP per 
molecule of glucose, it was hypothesized that the ATP generated through 
accelerated glucose consumption, would suffice to meet the energetic demands 
lost by uncoupling the TCA and oxidative phosphorylation from glycolysis 
(Koppenol et al., 2011; Vander Heiden et al., 2009). The enhanced lactate 
production could also be explained under this hypothesis as being essential for 
regenerating NAD from NADH. The glycolytic enzyme glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) requires NAD to transfer electrons from G3P, 
producing NADH in the process (Figure 1-2). This NADH is compartmentally 
restricted and must be regenerated in the cytosol. The reduction of pyruvate to 
lactate by lactate dehydrogenase (LDH) serves this function, replenishing the 
cytosolic NAD required by GAPDH. Lactate, largely an endpoint metabolite, is 
secreted rapidly, and is the primary reason for the increased extracellular acidity 
first noted by Warburg. Thus, LDH’s ability to process pyruvate into lactate to 
regenerate NAD is rate limiting for glycolysis and for the cell’s ability to consume 
glucose. Proliferation in glycolytic ‘Warburg-like’ cells is therefore contingent upon 
NAD regeneration in the cytosol.  
 
Today, the Warburg Effect is largely accepted as a universal manifestation of 
proliferation. Indeed, the current method for clinically identifying tumors in humans 
involves injecting radiolabeled glucose and imaging the body for concentrated 
areas of glucose consumption (Fukuda et al., 1982). Given its universal nature, 
aerobic glycolysis offers itself as an attractive target for therapeutic intervention in 
tumor cells. As a case in point, therapeutic targeting of LDHA with chemical 
inhibitors has recently gained momentum and is being introduced in clinical trials 
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(Hirschhaeuser et al., 2011; Rani and Kumar, 2016). Current technology allows us 
to focus in on the specific pathways involved in cancer metabolism and better 
understand how these pathways contribute to the physiological phenotypes noted 
by Warburg.  As the metabolic preferences of tumors have become clearer, 
questions pertaining to the adequacy of LDH’s capacity for NAD regeneration for 
aerobic glycolysis have emerged (Liberti and Locasale, 2016). 
 
One problem with Warburg’s model is stoichiometry. The Warburg hypothesis 
predicts that every molecule of glucose generates 2 molecules of NADH. These 2 
molecules of NADH will in turn need to be turned over by LDH with 2 molecules of 
pyruvate to replenish the NAD. Therefore, any diversion of glucose carbon away 
from glycolysis would be predicted to perturb the stoichiometry and stall glucose 
consumption. However, as discussed previously, the utilization of glucose carbons 
for biomass is integral to cell division (Lunt and Vander Heiden, 2011). Based on 
the above, we argued that alternative mechanism(s) must exist to regenerate the 
NAD required to sustain increased glycolysis.  
 
The role of glutamine in proliferative metabolism 
Warburg hypothesized that glycolysis could produce enough ATP to supply the 
cell, and his assessment of aerobic glycolysis included the suggestion that tumor 
cell mitochondria were devoid of a glucose carbon supply and either defective or 
inactive.  In fact, it is now accepted that proliferating cells harbor mitochondria that 
are largely functional but switch from glucose to glutamine as their primary carbon 
source. Glutaminolysis utilizes glutamine to generate mitochondrial alpha-
ketoglutarate (αKG) in a two-step process that supplies the TCA with the carbon 
needed to produce NADH and drive oxidative phosphorylation (Figure 1-3a). 
Glutaminase (GLS), the enzyme catalyzing the initial step of glutaminolysis, is 
expressed in many tumor cell types in response to transcription factors that drive 
proliferation such as Myc (Wise et al., 2008). The up-regulation of glutaminolysis 
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ensures that mitochondria continue to produce ATP while glucose is utilized for 
production of biomass needed for generating daughter cells.  
 
Glutamine as a source of biomass –reductive carboxylation 
Glutaminolysis produces αKG which is oxidized through the TCA serving as an 
anaplerotic for the generation of ATP. The increased glutamine consumption 
during proliferation and subsequent increase in αKG levels also drives reductive 
metabolism through isocitrate dehydrogenase (Fendt et al., 2013b). The resulting 
citrate is transported out of the mitochondria into the cytosol where ATP citrate 
lyase acts on it to produce acetyl-coA and oxaloacetate (OAA). This acetyl-coA is 
a major source for lipogenesis in response to hypoxia and metformin treatment, 
conditions that perturb oxidative phosphorylation (Fendt et al., 2013a; Mullen et 
al., 2011; Wise et al., 2011). The slowing of the TCA cycle in response to these 
Figure 1-3. Glutamine carbon utilization during proliferation. Schematic depicting 
how glutamine carbon, through glutaminolysis, provides the TCA with α-ketoglutarate (a). 
This allows NADH production and oxidative phosphorylation to continue when glucose 
carbon is diverted for biomass production. The α-ketoglutarate generated from glutamine 
is also reductively metabolized to produce cytosolic citrate that can be utilized for 
biomass (b). 
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stresses is acutely sensed at the αKG junction, which receives carbon input from 
both glucose and glutamine. This results in accumulation of αKG which then drives 
reductive metabolism (Figure 1-3b). The breakdown of cytosolic citrate by ATP 
citrate lyase also generates equimolar amounts of acetyl-coA and OAA. Many 
studies have reported the fate of the acetyl-coA that emerges from this step (Fendt 
et al., 2013a; Mullen et al., 2011; Wise et al., 2011), but the fate of cytosolic OAA 
has been less clear.  
 
Alpha-ketoglutarate plays a role in proliferation that is independent of metabolism 
The point of intersection where both glucose and glutamine carbons contribute to 
the TCA cycle serves as a sensor of nutrient supply as well as demand. As such, 
αKG, the metabolite at this intersection, has evolved as a messenger to signal the 
status of the TCA to the rest of the cell. As αKG accumulates it binds to non-
metabolic enzymes as a co-factor, influencing their activity. Enzymes such as the 
Ten eleven translocase (Tet) family of cytosine demethylases are activated by αKG 
eliminating epigenetic repression from gene promoters by allowing access to 
transcriptional machinery (Tahiliani et al., 2009). Histone demethylases, such as 
the Jumonji histone demethylase (JHDM), are also activated by αKG and similarly 
promote gene expression by relieving chromatin organization and allowing access 
to the transcriptional apparatus (Tsukada et al., 2006).  By influencing gene 
expression at the level of transcription, αKG can play a direct role in cell physiology 
(Figure 1-4). For example, naïve stem cells maintain pluripotency by consuming 
glutamine to elevate levels of αKG which, in turn, maintains histone and cytosine 
de-methylation(Carey et al., 2015). Another recent study showed that primed 
human stem cells treated with exogenous αKG increase global histone and DNA 
demethylation and differentiate independent of mitochondrial function (TeSlaa et 
al., 2016). αKG is also a co-activator of prolyl hydroxylases, which utilize 
atmospheric oxygen to hydroxylate proline residues on target proteins. The 
mechanisms highlighted here provide a link between metabolic function and cell 
physiology that cannot be understated, especially in the context of cancer where 
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glutamine consumption, glutaminolysis and αKG production are significantly 
increased.  
 
2-hydroxyglutarate is an oncometabolite 
The significance of the influence of αKG on cell physiology in the context of cancer 
came to light with the identification of isocitrate dehydrogenase (IDH) mutations in 
human glioblastoma (Parsons et al., 2008). It was found these mutations 
incompletely catalyze the conversion of αKG to citrate, yielding the intermediate 2-
hydroxyglutarate (Dang et al., 2009). The intracellular levels of 2-hydroxyglutarate 
(2-HG) increase dramatically in IDH mutant cells and outcompete αKG for co-factor 
activity on histone demethylases, cytosine demethylases and prolyl hydroxylases 
(Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012). The accumulated 2-
HG, resulting from IDH mutations, has transformative properties and can drive 
tumorigenesis by competitive inhibition of αKG (Losman et al., 2013). Since the 
oncogenic potential of 2-HG is attributed to its competition with ‘co-factor’ αKG 
competition, it stands to reason that αKG accumulation has tumor suppressor 
Figure 1-4. α-ketoglutarate’s effect on gene expression. Increased concentrations 
of α-ketoglutarate in cells activate histone and cytosine demethylases. Oncogenic 
mutations in isocitrate dehydrogenase generate 2-hydroxyglutarate that competitively 
inhibit α-ketoglutarate activation of these enzymes. The repression of α-ketoglutarate 
activated genes appears to be critical for tumor maintenance.  
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characteristics, although this idea has yet to be fully explored (Figure 4). Other 
groups have attempted to use αKG as a therapeutic in vitro and found that cell 
permeable αKG is toxic to some cell types (MacKenzie et al., 2007). 
 
We set out to investigate the role other dehydrogenases may play in regenerating 
cytosolic NAD during Warburg metabolism. We also looked at other carbon 
sources for this reaction including glutamine. The dependence on glutamine, and 
the accompanying increase in intracellular αKG levels, led us to investigate the 
resistance of cancer cells to elevated levels of this tumor suppressor metabolite.  
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Chapter 2 
 
MDH1 regenerates cytosolic NAD for glycolysis in 
proliferating cells 
  
	 12 
 
Introduction 
 
Aerobic glycolysis or the Warburg Effect is defined by the increased consumption 
of glucose accompanied by an increased production of lactate. The consumption 
of NAD and production of NADH by Glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH) is limiting to the glycolytic rate (Liberti and Locasale, 2016).  The 
Warburg Effect necessitates uncoupling of glycolysis from the TCA cycle as lactate 
dehydrogenase (LDH) activity is required for the rapid regeneration of NAD to 
sustain a high glycolytic rate. These basic parameters have been understood and 
accepted for nearly a century. However, newer technologies, including mass 
spectrometry-based targeted metabolomics that have allowed us to trace the fate 
of glucose carbon during proliferation, now show that a portion of glucose carbon 
is diverted away from glycolysis and towards the production of biomass during 
proliferation. The Warburg Effect requires every molecule of glucose to be 
metabolized to lactate to provide GAPDH with the NAD it needs for supporting 
accelerated glycolysis.  However, if glucose carbon is diverted to generate 
biomass needed for proliferation early during glycolysis, an additional source of 
NAD would be needed to maintain the high glycolytic rate and keep the process 
stoichiometrically viable. It is also important to note that lactate is a terminal 
metabolite which is secreted from the cell once it has served its purpose as an 
electron acceptor for the regeneration of NAD. We hypothesized that alternative 
reactions must exist to address the stoichiometry of NAD regeneration as well as 
allow a more efficient use of the resources available to the tumor. 
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Figure 2-1. Malate dehydrogenase regenerates cytosolic NAD in cancer cells. 
Schematic of [2H] labeling used to determine cytosolic NAD regeneration (a). Enrichment 
of M1 labeled metabolites from [4-2H] glucose 24 hours after labeling as measured by 
GC-MS in JPar (baseline glucose consumption) and N5 (high glucose consumption) cells 
(b). Peak area of indicated M+1 metabolites indicating the relative abundance of 2H 
incorporation in JPar and N5 cells (c). Significance was calculated using the student’s T 
test (* p<0.01, ** p<0.001). 
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Results 
 
Malate dehydrogenase 1 contributes to NAD regeneration during increased 
glycolysis. 
Previous work from our lab had characterized a Jurkat leukemia cell model in 
which the over-expression of the Bcl-2 family protein Noxa increased glucose 
consumption and proliferative rate (Lowman et al., 2010).  Despite the increased 
glucose consumption, the rate of glucose carbon flow to the distal steps in 
glycolysis decreased in the Noxa over-expressing cells, suggesting that glucose 
carbon was being diverted prior to the production of lactate (Lowman et al., 2010). 
The ideal way to assess the consequences of the Warburg effect would be to 
directly compare matched normal and tumor cells.  However, emerging tumors 
acquire several genomic, transcriptomic and proteomic characteristics that 
confound direct comparison with normal tissue. Our Jurkat cell model of Noxa 
over-expression (N5), exhibits a Warburg-like phenotype following modulation of a 
single gene, allowing such a comparison with significantly less noise.  
 
To investigate NAD regeneration in the Jurkat N5 Warburg model, we used 2H-4 
glucose which transfers the deuterium, [2H], to NADH as GAPDH generates 3-
phosphoglycerate from glycerol 3-phosphate (Figure 2-1a).  This deuterium should 
then label cytosolic metabolites produced in dehydrogenase reactions that 
regenerate NAD downstream. We can conclude these reactions are restricted to 
the cytosol as no mitochondrial NADH transporters exist. 
 
We fed cells with 2H-4 glucose for 24 hours and used gas chromatography coupled 
mass spectrometry (GC-MS) and liquid chromatography coupled mass 
spectrometry (LC-MS) to trace metabolites labeled with deuterium in slowly 
proliferating (JPar) and highly proliferating/Warburg-like (N5) cells. We found 
lactate represented the largest scenario the a-carbon of aspartic acid would be 
predicted to be labeled with deuterium (Lamesch et al., 2007; Yang et al., 
	 15 
2003)(Figure 2-2a). We performed NMR analysis to determine which carbon of 
aspartate was labeled (Figure 2-2b). We found that the deuterium was present not 
on the a-, but on the b-carbon. This could be explained by fumarate, a symmetrical 
molecule, returning through malate and oxaloacetate as a separate enantiomer 
and then to aspartate via aspartate transaminase. Thus, we concluded that both 
fumarate and aspartate labeling were additional metrics of malate labeling.  
 
Figure 2-2. Aspartate dehydrogenase is not responsible for aspartate labeling. The 
aspartate dehydrogenase reaction as predicted by Yang et al in Thermotoga maritima 
and the aspartate labeling observed following [4-2H] glucose labeling in N5 cells (a). NMR 
tracing for 1H in the α and β carbon of aspartate following [4-2H] glucose labeling. The 
partial depletion of 1H on the β carbon indicates 2H has replaced the 1H (b).  
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We used primary human T cells as an additional model to investigate MDH1 
activity during proliferation. When stimulated using anti-CD3/anti-CD28 antibodies, 
T cells proliferate rapidly and increase aerobic glycolysis (Carr et al., 2010; 
Frauwirth et al., 2002). The activation of T cells also promotes the diversion of 
glucose carbon to support biomass synthesis (Carr et al., 2010; Frauwirth et al., 
2002). We found T cells also significantly increased M1 labeling of malate after 24 
hours of activation suggesting that increased MDH1 activity plays a role in robust 
proliferation and is not exclusive to the N5 model (Figure 2-3a).  
 
We next looked at the flux dynamics of malate and lactate labeling in the HeLa 
ovarian cancer cell line which is highly glycolytic and has been used as a model 
for studying Warburg metabolism ((Goldberg and Colowick, 1965; Pike Winer and 
Wu, 2014)). Labeled malate reached steady state at 3 hours suggesting that it was 
the product of a robust synthesis reaction using a readily available source of 
oxaloacetate. Labeling dynamics for M1 malate were similar to M1 lactate, the 
main Warburg readout (Figure 2-3b). The malate aspartate shuttle (MAS) is a 
system by which NAD regeneration in the cytosol can be utilized for NADH 
production in the mitochondria. The MAS includes MDH1 and passes the malate 
into the mitochondria for MDH2 to reverse the reaction and produce mitochondrial 
NADH which can contribute to the electron transport chain. The role of the MAS 
during the Warburg effect has not yet been elucidated. We observed that HeLa 
cells secrete a substantial amount of labeled malate (Figure 2-3c) and this 
suggests in HeLa cells the malate produced by MDH1 is overwhelming other 
malate utilizing reactions, including the MAS. To our knowledge, this is the first 
evidence that malate generated in the cytosol is secreted and may contribute more 
to the overall extracellular acidification than previously appreciated.  
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Figure 2-3. Malate dehydrogenase regenerates cytosolic NAD in primary 
activated T cells and HeLa cells. Primary human T cells labeled with [4-2H] glucose 
for 24 hours indicate malate dehydrogenase 1 is utilized to regenerate cytosolic NAD 
following activation (a). Flux labeling of [4-2H] glucose in HeLa cells shows steady state 
is reached within 3 hours whereas lactate is still approaching steady state at 12 hours 
(b). Spent medium from the experiment shown in (b.) demonstrate malate is excreted 
from HeLa cells (c). Significance was calculated using the student’s T test (* p<0.01). 
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Deletion of Malate dehydrogenase 1 slows growth and glucose consumption  
To better understand the role of MDH1 in supporting growth and glycolysis, we 
obtained Jurkat T-ALL cells knocked out for MDH1 by CRISPR/Cas9 (Birsoy et al., 
2015). Compared to wild-type controls, MDH1 KO cells grew significantly slower 
and consumed less glucose per cell (Figure 2-4a-b). We reasoned that the 
decreased growth in MDH1 KO cells should be rescued by the addition of pyruvate. 
The exogenous pyruvate would supply LDHA independent of glycolytic rate and 
give the cell a direct substrate to restore the NAD regeneration capacity of the cell. 
Indeed, the addition of pyruvate rescued MDH1 deficient cells (Figure 2-4c). 
Overall, these data demonstrate NAD regeneration by MDH1 is critical for the 
proliferative capacity and glucose consumption rate of Jurkat T-ALL cells. 
 
LDHA inhibition is only effective in the absence of MDH1. 
The universal nature of the Warburg effect in proliferating cells has inspired 
therapeutic strategies that are aimed at limiting the glucose consumption of the 
tumor. One such strategy aims to cut off the NAD supply to GAPDH by targeting 
lactate dehydrogenase. Indeed, LDHA inhibition is a strategy that is entering 
clinical trials (Augoff et al., 2015; Billiard et al., 2013; Rani and Kumar, 2016). Our 
findings suggest the redundancy provided by MDH1 may render these therapies 
ineffective, at least in the context of T-ALL. To investigate this idea, we first looked 
at how the activity of LDHA changes when MDH1 is deleted. The basal 
extracellular acidification rate of MDH1 KO cells is significantly higher than that of 
wild-type cells, indicating that reliance on LDHA for NAD regeneration is increased 
in the absence of MDH1 (Figure 2-5a). We hypothesized that LDHA inhibition 
would have little effect on cell growth or glucose consumption in the presence of 
MDH1. 
	 19 
 
Figure 2-4. Loss of MDH1 slows proliferation and glucose consumption. 
Western blot showing protein expression of MDH1 and LDHA in control and MDH1 
KO Jurkat cells (a). Graph shows cell number over time for indicated cell lines (b). 
Cells were plated at 50,000 cells per ml and counted every 24 hours. Glucose levels 
in the spent medium were determined on day 3 and normalized to cell number (c). 
MDH1 KO.1 and KO.2 cells were counted at 1, 3 and 5 days after addition of 1mM 
sodium pyruvate added to RPM1-1640, a pyruvate deficient medium (d). Data are the 
average and standard deviation of samples from experiments repeated at least three 
times.  Significance was calculated using the student’s T test (* p<0.01, ** p<0.001).  
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We used the LDHA inhibitor GSK2837808A which decreases lactate production 
(Figure 2-5b) and has been shown to inhibit the growth of colon cancer cells 
(Billiard et al., 2013; Xie et al., 2014). We found that in the presence of MDH1, 
LDHAi had no effect on cell growth. However, in the absence of MDH1, LDHA 
significantly decreased cell growth almost to the point of becoming cytostatic in the 
case of MDH1 KO.2 (Figure 2-5c).  
 
We also observed a significant decrease in glucose consumption in MDH1 KO 
cells treated with LDHAi (Figure 2-5d). Interestingly, glucose consumption by wild-
type cells treated with the LDHA inhibitor was dramatically increased (Figure 2-
5d). As discussed earlier, the utilization of glucose carbon for lactate production is 
wasteful, especially during tumor emergence when access to glucose is limiting. 
Malate dehydrogenase 1, which provides an alternative NAD regeneration 
mechanism, may allow for more glucose to flow into alternative pathways. This 
observation also implies that oxaloacetate, the substrate for MDH1 is either readily 
available in the cytosol or derived from a glucose independent carbon source, or 
both.  
 
These results suggest MDH1 and LDH work together in a redundant manner to 
regenerate NAD and support glycolysis in cancer cells, and that reliance on MDH1 
could provide a proliferative advantage during the Warburg effect.  
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Figure 2-5. Loss of MDH1 sensitizes cells to LDH inhibition. Extracellular acidification 
rate measured by Seahorse in Wt and MDH1 knock-out Jurkat cells (a). Extracellular 
lactate levels in the medium of DMSO (Veh) or GSK2837808A (LDHAi) treated cells 48 
hours after administration and normalized to cell number (b). Cell concentrations on the 
indicated days following treatment with either DMSO (Veh) or GSK2837808A (LDHAi) (c). 
Glucose levels in the spent medium from day 3, normalized to cell number and shown 
relative to levels detected in vehicle treated cell medium (d). Data are the average and 
standard deviation of samples from experiments repeated at least twice.  Significance was 
calculated using the student’s T test (* p<0.01, ** p<0.001). 
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MDH1 amplification is prominent in human tumors and correlates with poor 
prognosis.   
Our data suggested MDH1 provided a benefit to tumor growth and glucose 
consumption. Thus, we hypothesized human tumors would benefit from MDH1 
amplification. We queried The Cancer Genome Atlas using the cBioportal (Cerami 
et al., 2012; Gao et al., 2013) to investigate incidences of genomic aberrations in 
the MDH1 gene. We found that MDH1 was rarely mutated suggesting functional 
MDH1 enzymatic activity is prominent in human tumors (Figure 2-6a). We found 
that amplification was the most common genomic aberration, with occurrence as 
high as 11% in lung squamous cell carcinoma. (Figure 2-6b). Patients within this 
dataset with genomic amplification of MDH1 showed more than a 50% decrease 
in survival rate suggesting MDH1 amplification correlates with more aggressive 
tumors (Figure 2-6c). The MDH1 gene is located on chromosome 2p13 which has 
not been reported to be a common amplification segment and is not adjacent to 
known oncogenes. Rather, we argue MDH1 amplification is an acquired aberration 
that provides a proliferative benefit by enhancing the ability to process glucose for 
biomass production. When we queried MDH1 aberrations in tandem with LDHA, 
we found that MDH1 was amplified more frequently than LDHA in all the tumor 
types we investigated (Figure 2-6d). Furthermore, these amplification events were 
mutually exclusive underscoring the redundancy of these enzymes (Figure 2-6d). 
The frequency of MDH1 amplification events and aggressive nature of MDH1 over-
expressing tumors help validate the hypothesis that MDH1 plays an important role 
in supporting tumor proliferation.  
 
We next asked whether the over-expression of MDH1 was sufficient to accelerate 
anchorage independent growth, a readout for tumorigenicity. We used the A549 
lung cancer model which has been reported to be highly dependent on LDHA 
inhibition (Liu et al., 2014; Xie et al., 2014). We found that stable over-expression 
of MDH1 in A549 cells (Figure 2-7a) significantly increased the number of colonies 
formed in soft agar indicating that MDH1 expression  
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increases anchorage independent cell growth (Figure 2-7b). These data also 
predict that relieving dependence on LDHA with MDH1 is a potential mechanism 
of resistance to therapeutic targeting of LDHA.  Next, we wanted to determine 
whether the proliferative rate of MDH1 KO cells could be rescued by restoring 
MDH1 expression. Stably re-expressed MDH1 in MDH1 KO.2 cells significantly 
restored the proliferative rate (Figure 2-7c).  
Taken together, these results demonstrate that over-expression or amplification of 
MDH1 provides a proliferative advantage to cancer cells. 
 
 
Figure 2-6. MDH1 is amplified in human cancers and correlates with poor 
prognosis. The Cancer Genome Atlas online database was queried using cBioportal 
software to query MDH1 mutations (a). All MDH1 expression aberrations, including 
amplification, deletions and mutations in human tumors were queried (b). The lung 
squamous cell carcinoma subset was further interrogated to correlate MDH1 
amplification with disease free survival (c). MDH1 and LDHA queried together for 
genomic aberrations in the lung squamous cell carcinoma dataset (d).   
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Figure 2-7. MDH1 over-expression increases anchorage independent growth. 
Western blot demonstrating expression of MDH1-FLAG in stably transfected A549 cell 
lines (a). Representative low magnification microscopic images of colony numbers and 
sizes at 14 days (b). Colony counts after 2-week soft agar colony formation assays.  The 
average number of colonies from ten low-magnification microscopic fields from triplicate 
wells is shown (c). MDH1 KO.2 Jurkat cells were stably transfected with MDH1-FLAG or 
lacZ and plated at 10,000 cells per ml. Cell concentration was plotted on days 1, 3 and 5 
(d). Data represented are the average and standard deviation of triplicate samples from 
a representative experiment repeated at least twice. Significance was calculated using 
the student’s T test (* p<0.01, ** p<0.001). 
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Conclusions 
 
In this chapter, we demonstrate that malate dehydrogenase 1 activity supports the 
regeneration of NAD during aerobic glycolysis in proliferating cells and in cancer. 
Limiting the glucose uptake potential of a cancer cell is an attractive therapeutic 
strategy as the Warburg phenomenon is a nearly universal hallmark of tumors. 
Currently the field is looking to target the cytosolic NAD regenerating capacity of 
the tumor cell with the goal of limiting the cell’s ability to process glucose and slow 
down its consumption. Current glycolysis targeting strategies are focused on the 
NAD regenerating enzyme lactate dehydrogenase. Our findings suggest that 
malate dehydrogenase 1 intervention will also be required to fully limit the NAD 
regeneration potential of the cell. Besides, the inhibition of LDHA will likely drive 
resistance through MDH1. Our results, as well as data from TCGA suggest the 
switch to MDH1 could result in more aggressive tumors that use a more efficient 
pathway of glucose independent carbon to regenerate NAD. The product of the 
MDH1 reaction, malate, is a substrate for many other catabolic reactions beneficial 
for proliferation.  
 
The next step was to determine the carbon source for the MDH1 reaction. 
Oxaloacetate, the substrate for MDH1 is likely independent of glucose as forcing 
cells to utilize MDH1 results in more robust glucose consumption (Figure 2-6d). 
The source of oxaloacetate is also readily available in the cytosol as demonstrated 
by labeling dynamics which had indicated that M1 malate labeling from 2H 4-
glucose reached steady state by three hours. We set out to identify the source of 
cytosolic OAA used by MDH1 to produce malate and regenerate NAD. 
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Chapter 3 
Cytosolic MDH1 utilizes glutamine-derived carbons to 
support glycolysis 
  
	 28 
Introduction 
 
The findings described in the previous chapter demonstrate a critical role for 
malate dehydrogenase 1 (MDH1) in the regeneration of cytosolic NAD to sustain 
the increased glycolysis associated with proliferation.  We were interested in the 
carbon source of cytosolic oxaloacetate (OAA), the MDH1 substrate. Flux 
experiments had suggested the substrate for the MDH1 reaction was not only 
readily available but likely to be independent of glucose carbon. Thus, we surmised 
that MDH1 must use alternative carbon sources to produce malate and cytosolic 
NAD. Besides glucose, glutamine is a major carbon source for the citric acid cycle 
in proliferating cells. Glutamine, like glucose, is abundant in the blood. Although it 
is a non-essential amino acid, proliferating cells prefer increasing the uptake and 
breakdown of exogenous glutamine to generating it de novo. Glutamine carbon is 
metabolized via glutaminolysis in two steps to alpha-ketoglutarate (aKG) which 
enters the TCA cycle in the mitochondria. The diversion of glucose carbon to 
lactate production during the Warburg effect renders essential the use of 
glutamine-derived aKG as an anaplerotic for maintaining the TCA cycle and for 
oxidative phosphorylation. Interestingly, the rate of oxidative phosphorylation 
decreases substantially in proliferating cells suggesting glutamine is also 
metabolized via alternative routes (Fendt et al., 2013b; Lum et al., 2007; Wise et 
al., 2011). Glutamine carbons, much like those of glucose, support both energy 
production as well as the biosynthesis of nucleotides, amino acids and NADPH 
that are so critical for proliferation. Next, we investigated the role of glutamine in 
providing carbon for the MDH1 reaction. 
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Results 
 
Glucose carbon is diverted prior to lactate in Noxa over-expressing cells. 
In a previous study, we showed Noxa over-expressing cells (N5) consumed 
glucose faster than controls but much of that glucose failed to complete glycolysis 
(Lowman et al., 2010). This suggested the increased glucose carbon consumed 
by N5 cells was diverted into alternative pathways. To gain better insight into how 
glucose was utilized in N5 cells we used 13C-1,2 glucose to trace the fate of glucose 
carbons (Figure 3-1a). We found N5 cells increased the percentage of labeled pool 
(M+2) in early glycolysis as far as the glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH) reaction, but not beyond, and decreased overall glucose carbon 
contribution to the TCA (Figure 3-1b-1c). These data are consistent with a previous 
study from our lab showing  a reduction in the amount of 3H water produced in the 
phosphenolpyruvate step in 3H-glucose labeled N5 cells compared to JPar controls 
(Lowman et al., 2010), suggesting that lactate dehydrogenase was not being 
supplied with sufficient glucose carbon to sustain increased glycolysis beyond the 
GAPDH step. N5 cells diverted a significant amount of glucose carbon into the 
pentose phosphate pathway (PPP) that supplies NADPH for the control of reactive 
oxygen species (ROS) and de novo lipogenesis. Two molecules of NADPH are 
generated from every molecule of glucose 6 phosphate that enters the PPP.  
Figure 3-1. Noxa over-expressing cells increase glycolysis but not lactate 
production from glucose. Schematic tracing the incorporation of [13C] label from [1,2-
13C] glucose (red) through glycolysis and the TCA cycle, and [U-13C] glutamine (blue) into 
TCA cycle metabolites (a). Glycolysis metabolites labeled from [1,2-13C] glucose 
following 24 hours of labeling, shown as a percentage of total metabolite measured using 
LC/MS (b). G6P: glucose 6 phosphate, FBP: fructose 1,6 bisphosphatase, G3P: 
glyceraldehyde 3 phosphate, 2PG/3PG: phosphoglycerate. TCA metabolites labeled 
from glucose carbon measured via LC/MS following 24 hours of labeling (c). Data 
represented are the average and standard deviation of triplicate samples from a 
representative experiment repeated at least twice. Significance was calculated using the 
student’s T test (* p<0.01, ** p<0.001).  
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Figure 3-2. Noxa over-expressing cells direct glucose carbon into the pentose 
phosphate pathway. Simplified schematic diagram of the pentose phosphate pathway 
(PPP) tracing glucose carbons through portions of the oxidative and non-oxidative arm 
(a). Noxa overexpressing cells increase glucose carbon flux to the non-oxidative phase 
of the pentose phosphate pathway (b). Experiments were performed as in Figure 4 
using [1,2-13C] D-glucose as a label. Shown is percent enrichment of M1 label from 
glucose into R5P and M2/M3 into S7P per the schematic in (a). R5P: ribose 5 
phosphate/ribulose 5 phosphate (oxidative PPP metabolite). S7P: sedoheptulose 7 
phosphate (non-oxidative PPP metabolite). 
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However, the carbon from the PPP is limited to two fates. The oxidative path results 
in the generation of ribose 5 phosphate (R5P), used for the generation of de novo 
nucleotides. The other (non-oxidative) option returns the carbon to glycolysis 
(Figure 3-2a). We found N5 cells increased glucose carbon to sedoheptulose 7 
phosphate (S7P, non-oxidative), but not to R5P (oxidative), indicating that the non-
oxidative arm of the PPP is accelerated in these cells (Figure 3-2b). Furthermore, 
these results suggest that some of the carbon lost to the PPP returns to glycolysis.  
 
Noxa overexpressing cells utilize glutamine carbon for TCA and for cytosolic 
metabolites generated through reductive carboxylation. 
Since N5 cells did not metabolize glucose carbon beyond G3P or into the TCA 
cycle, (Figure 3-1c) we asked whether glutamine served as an alternative carbon 
source for the TCA in these cells. Many cancer cells and proliferating normal cells 
are dependent on glutamine as a carbon source for both biomass production as 
well as TCA metabolism (Fendt et al., 2013b; Lum et al., 2007; Wise et al., 2011) 
(Figure 3-3a). We fed N5 and JPar cells with 13C-U glutamine and traced the fate 
of 13C using targeted metabolomics. We found that rate of glutamine uptake was 
similar in both cell types (Figure 3-3b). However, N5 cells increased the rate of 
conversion of glutamine to glutamate as well as to TCA intermediates aKG, 
fumarate and malate. Thus, N5 cells utilize glutamine carbon to support the 
continued activity of the TCA cycle when glucose carbon is diverted to anabolic 
processes for generating biomass.  
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Glutamine metabolism in proliferating cells has also been shown to be important 
for biomass production. One particularly important step for glutamine metabolism 
is the reductive carboxylation of mitochondrial aKG into citrate (Figure 3-3a). IDH 
enzymes catalyze this reaction bi-directionally and are therefore, dependent on the 
aKG citrate ratio in the mitochondria (Fendt et al., 2013b). As proliferating cells 
increase glutamine consumption and aKG production through glutaminolysis, the 
direction of aKG metabolism can vary. The excess citrate generated by reductive 
carboxylation is exported into the cytosol where it is broken down into acetyl-CoA 
and oxaloacetate. The acetyl-CoA generated in this manner has been shown to be 
a major substrate for lipid synthesis in tumor cells (Wise et al., 2011). However, 
the fate of the OAA is less clear although cytosolic OAA would be predicted to be 
a substrate for MDH1.  
We calculated the total pools of aKG and citrate in JPar and N5 cells. Finding the 
aKG to citrate ratio was 33% higher in N5 cells (not shown) we reasoned that the 
reductive carboxylation of glutamine could play a role in providing the OAA 
substrate for MDH1 in the cytosol.  Labeling with 13C-U glutamine allows for 
evaluating of both oxidative and reductive aKG metabolism (Figure 3-3a). We 
Figure 3-3. Noxa over-expressing cells increase reductive carboxylation of 
glutamine to support cytosolic malate production. Schematic tracing the 
incorporation of [13C] label from [U-13C] glutamine metabolized in oxidative (royal blue) 
and reductive (light blue) directions (a). Enrichment of glutaminolytic and TCA 
metabolites derived from [U-13C] glutamine following 24 hours of labeling, detected using 
LC/MS (b). Gln: glutamine, Glu: glutamate, αKG: alpha-ketoglutarate, Fum: fumarate. 
Number of labeled carbons is indicated in parentheses. Percent enrichment of citrate 
and acetyl-CoA derived from reductive carboxylation of [U-13C] glutamine 24 hours after 
labeling, determined via LC/MS (c). Percent enrichment of glutamine carbon into 
palmitate (d). Pool abundance of indicated metabolites in JPar and N5 cells quantified 
by peak area and normalized to sample protein concentration (e). Percent enrichment 
of citrate, malate and aspartate derived from reductive carboxylation of [U-13C] glutamine 
in primary human T cells 24 hours after labeling and activation. (f) Pool abundance of 
indicated metabolites in unstimulated and stimulated primary human T cells quantified 
by peak area and normalized to sample protein concentration. Isotopomer label 
indicated in parenthesis below metabolites.   Data presented are the average and 
standard deviation of triplicate samples from a representative experiment repeated at 
least twice. Significance was calculated using the student’s T test (* p<0.01, ** p<0.001). 
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found N5 cells increased the production of reductively generated citrate and acetyl-
CoA (Figure 3-3c). Although our assay was unable to identify OAA, acetyl-CoA 
and OAA are 1:1 with the lysis of citrate. This acetyl-CoA is often the substrate for 
de novo lipogenesis in other cancer cells. However, we found instead that N5 cells 
decreased incorporation of reductively generated acetyl-CoA into palmitate (Figure 
3-3d). The fate of the acetyl-CoA produced from the reductive carboxylation of 
glutamine remains unclear. We argue that the breakdown of citrate in N5 cells was 
aimed at OAA production rather than acetyl-CoA.  
 
We next looked at downstream metabolism of the OAA that was produced by 
reductive carboxylation of glutamine. N5 cells significantly increased percent 
enrichment of glutamine carbon into malate, but not into aspartate, demonstrating 
glutamine carbon is a source for the MDH1 reaction and increases during aerobic 
glycolysis. Importantly, the peak areas for the reductive metabolism of glutamine 
carbon demonstrate a clear increase in labeled pool totals for the pathway leading 
to MDH1 (Figure 3-3e). Primary activated T cells also increase MDH1 activity in 
parallel with aerobic glycolysis (Figure 3-3f). We found that stimulation of T cells 
also produced a significant amount of cytosolic malate through reductive 
carboxylation. Interestingly, although the percentage of labeling of reductively 
generated aspartate significantly increased in stimulated T cells, the pool size of 
labeled aspartate was lower suggesting the fate of cytosolic OAA favored MDH1 
over aspartate transaminase (Figure 3-3g). Overall, these data demonstrate that 
the increased activity of MDH1 during aerobic glycolysis, is fueled by OAA 
generated through the reductive carboxylation of glutamine. 
 
Jurkat cells require MDH1 for dependence on glutamine. 
Our previous findings suggest flux through reductive carboxylation was a major 
draw for glutamine carbon and that OAA from glutamine was supplying MDH1 with 
the ability to regenerate cytosolic NAD and support glycolysis. To further test this 
idea, we cultured MDH1 wt and KO cells in medium with low or high  
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Figure 3-4. Glutamine dependence is lost in MDH1 knock out cells. MDH1 wild-
type and knock-out cells were cultured in normal (2mM) or low (0.5mM) glutamine for 
7 days. Cells were counted at 1, 3, 5 and 7 days. Data presented are the average and 
standard deviation of quadruplicate samples from a representative experiment 
repeated at least twice (a). Simplified model to show how malate dehydrogenase 1 
and glutamine help support the increased glucose uptake and glycolysis by 
replenishing the NAD consumed by the GAPDH catalyzed step, a function primarily 
attributed to LDH activity in highly glycolytic cells.  Our studies suggest that, in 
proliferating cells, MDH1 is a significant alternative source of cytosolic NAD, utilizing 
the carbons from the reductive carboxylation of glutamine for the NADH dependent 
synthesis of malate (b).	
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glutamine and monitored their growth. Only MDH1 wt cells were sensitive to low 
glutamine concentrations supporting the idea that a major source of glutamine 
carbon in proliferating cells is the MDH1 reaction (Figure 3-4a).  
 
Conclusions 
 
Glutamine is well recognized as a critical carbon source during proliferation (Fendt 
et al., 2013b; Lum et al., 2007; Wise et al., 2011). The oxidation and reductive 
metabolism of glutamine carbon have both been reported to play significant roles 
in proliferative metabolism. Here, we demonstrate a new role for glutamine carbon 
in supporting glycolysis.  By supplying cytosolic oxaloacetate for NAD regeneration 
by MDH1, glutamine carbon helps support the increased glucose consumption and 
biomass production in proliferating cells. Previous studies have reported that the 
primary role of reductive carboxylation of glutamine was to provide the acetyl-CoA 
needed for de novo lipogenesis (Lum et al., 2007; Wise et al., 2011), but little was 
known about the contribution of oxaloacetate, the other by-product of citrate lysis. 
Our studies are the first to suggest that the role of reductive carboxylation extends 
beyond supplying acetyl-CoA for lipid generation to include provision of carbon 
substrates for MDH1 activity. Using glutamine carbons for cytosolic NAD 
regeneration frees up glucose carbons for biomass diversion, and relieves lactate 
dehydrogenase of shouldering the burden of NAD regeneration on its own. Taken 
together with the studies described in Chapter 2, which show that LDH inhibition 
increases glucose consumption in Jurkat cells, our data point to a major role for 
glutamine and MDH1 in replenishing the NAD required for glycolysis reveal a 
potentially valuable therapeutic opportunity (Figure 3-4b). The dependence on, 
and increased consumption of, glutamine also revealed another potential 
vulnerability in cancer cells that captured our interest. Glutamine metabolism via 
the reductive carboxylation route occurs when the concentration of αKG in the 
mitochondria increases and is higher than citrate, one of the most abundant 
metabolites in the cell (Fendt et al., 2013b). Concentrations of αKG this high in the 
cell have other profound effects on proliferation as αKG can affect gene expression 
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through co-factor activity. Mutations in isocitrate dehydrogenase, the enzyme that 
produces αKG, are believed to be oncogenic drivers in glioblastomas and myeloid 
leukemias. Other studies have reported that increased concentrations of cellular 
αKG decrease proliferative potential and drive differentiation (Carey et al., 2015; 
Tennant and Gottlieb, 2010). In the following chapters, we explore the idea that 
elevated concentrations of the metabolite αKG affect cell growth, proliferation and 
survival by regulating gene expression. 
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Chapter 4 
Resistance to chronic αKG treatment 
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Introduction 
 
Cancer metabolism, at its surface is a reactive adaptation to the demands of cell 
division. The impetus for metabolic change is the up-regulation of proliferative 
pathways that call for diversion of carbon sources into the de novo generation of 
biomass. However, it is becoming increasingly clear that metabolites on their own 
have signaling capacity that can influence the physiology of a cell, including its 
proliferative potential. Since the potential to successfully perform cell division is 
closely tied to nutrient availability, it is not surprising that metabolites have evolved 
the ability to relay signals to the rest of the cell. Nutrient concentrations signal to 
the cell nutrient availability as well as the capacity for consumption. Our findings, 
showing that glutaminolysis and glutamine carbons support and regulate glucose 
consumption, are linked to this idea and served as a starting point for the studies 
described in this chapter (Hanse et al., 2017).  
 
Inputs from both glucose and glutamine carbon intersect at alpha-ketoglutarate 
(aKG) in the TCA cycle (Figure 1-2), making accumulation of this metabolite a 
critical indicator of nutrient availability. Moreover, aKG is positioned early in the 
TCA cycle where accumulation could also signal decreased mitochondrial function 
or a decreased demand for electron transport. The cellular concentration of aKG 
could thus serve as a ‘messenger’, signaling metabolic fitness to the rest of the 
cell.  
 
This message is relayed through an enzymatic co-factor function of aKG that is 
independent of metabolism. aKG binds to the active sites of DNA and histone 
demethylases and potentiates their activity. The removal of methylation moieties 
from cytosines within gene promoter regions can regulate access of RNA 
polymerase and influence gene expression (reviewed in (Fazzari and Greally, 
2004)). 
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The importance of aKG in epigenetic regulation, particularly in the context of 
cancer became evident when it was discovered that glioblastomas and myeloid 
cell leukemias harbor mutations in isocitrate dehydrogenase (IDH), the enzyme 
that produces aKG from isocitrate.  Specific mutations in the active site of IDH 
cause an incomplete reaction that results in the production of 2-hydroxyglutarate 
(2-HG), a metabolite that resembles aKG but is not readily metabolized in the cell. 
The accumulation of 2-HG was found to be oncogenic in that it represses 
differentiation and promotes stem like qualities (Figueroa et al., 2010; Losman et 
al., 2013; Lu et al., 2012). The oncogenic nature of 2-HG is manifest through 
competitive inhibition of aKG’s co-factor function at these histone and cytosine 
demethylases.  
 
If 2-HG is an oncogenic metabolite that functions through competitive inhibition of 
aKG, we reasoned that aKG accumulation could have tumor suppressive effects. 
Little is known regarding the specificity of genes or gene networks regulated by 
aKG dependent methyltransferases. Most studies have looked at global 
physiologic responses to aKG rather than its regulation of specific genes. We 
predict that aKG regulated gene responses are targeted and regulated, as 
indiscriminate, global, DNA/histone demethylation would be catastrophic to cancer 
cells. 
 
We set out to identify specific genes and gene networks affected by aKG 
accumulation in cancer cells, predicting that these findings would offer a better 
understanding of the pathways involved in 2-HG dependent cancers, such as 
glioblastomas and myeloid leukemias. These findings could also potentially inform 
novel therapies targeted at aKG related pathways in a variety of cancers.  
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Results 
 
Clonal Jurkat cells display a spectrum of sensitivities to aKG.  
We evaluated the response of clonal lines derived from a heterogenous parental 
population of Jurkat human T leukemia cells to cell permeable (dimethyl) aKG 
(DM-αKG), and found a wide spectrum of sensitivities within the Jurkat population 
(Figure 4-1a). We asked whether the aKG sensitivity in clone 3 was a result of 
metabolic catastrophe or a reflection of the non-metabolic functions of aKG. To 
distinguish between the two possibilities, we attempted to rescue cell death with 2-
hydroxyglutarate, an analog of aKG that functions as a competitive inhibitor of aKG 
rather than a metabolite. Sensitive clone 3 cells were rescued from cell death in a 
Figure 4-1. Varying sensitivities 
to α-ketoglutarate in cancer 
cells. Jurkat cells were single cell 
cloned and treated with 4mM αKG 
in the absence of glutamine for 24 
hours. Shown is the viability as 
assayed by the annexin-
V/propidium iodide death assay 
(a). Clone 3 (αKG sensitive) and 
Clone 1 (αKG resistant) were 
treated with αKG as in (a) and 
rescued with cell permeable octyl 
ester 2-hydroxyglutarate (OE-2-
HG) (b). Human colorectal cell 
lines (DLD1, HCT116) and human 
lung cancer cell lines (A549, 
H522) were treated with 4mM 
αKG in the absence of glutamine 
for 24 hours. Viability was 
assayed via trypan blue exclusion 
(c). 
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dose dependent manner by the addition of 2-HG, suggesting that aKG was 
inducing cell death through mechanisms independent of metabolism (Figure 4-1b). 
We then tested commonly studied colorectal and lung cancer lines for their 
response to aKG and found variable sensitivities in these models as well (Figure 
4-1c).  
 
A high throughput screen to identify changes in the proteome brought about by 
chronic aKG treatment. 
Little is known about the global effect on gene expression induced by persistently 
high levels of aKG concentration. To better understand the physiological effects of 
aKG treatment, we designed a high-throughput experiment to compare the 
proteomes of cells that were sensitive or resistant to aKG. We chose chronic 
treatment over acute as the pathways up-regulated after longer periods of time 
would be stable and more significant for survival in the presence of aKG.   
 
We used Jurkat parental cells, which harbor a mixture of aKG sensitive and 
resistant cells (Figure 4-1a). We cultured the initial Jurkat parental cells in medium 
containing 4mM DM-aKG until a population emerged that proliferated at a 
comparable rate to untreated cells (approximately 30 days, data not shown). We 
followed this with a mass spectrometry based quantitative proteomics method, 
iTRAQ (Wiese et al., 2007), that compared the proteome of aKG resistant cells to 
that of the parental population, maintained in culture in parallel (Figure 4-2a). This 
method labels peptides with mass addition “barcodes” that allow analysis software 
to assign sample of origin from a mixture of samples (Figure 4-2a).  Using both 
Protein Pilot and MaxQuant analysis software, we generated a list of over 1,000 
significantly regulated proteins in aKG resistant cells (See Materials and Methods 
chapter for more details). The heat map for the most significantly regulated 
proteins using a maximum threshold for peptide identification is shown in Figure 4-
2b. We also generated a list of the ‘most regulated’ proteins using less stringent 
exclusion criteria for peptide identification (Figure 4-3a). One of the most up-
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regulated proteins in aKG resistant cells was citrate synthase (Figure 4-3a). To 
validate the iTRAQ screen, we single cell cloned the aKG resistant population by 
limit dilution and performed Western blot for citrate synthase. We found that almost 
all aKG resistant clones we tested had significantly increased citrate synthase   
Figure 4-2. Chronic treatment with αKG causes significant changes to the 
proteome of Jurkat Cells. Schematic representing the generation of an αKG resistant 
population following chronic treatment (a, left). Schematic of the iTRAQ proteomics 
screen used to identify characterize the proteome of parental and αKG resistant cells (a, 
right). Heat map indicating the 100 most regulated proteins identified from iTRAQ via 
ProteinPilot software using a list generated from peptides with a high identification 
significance threshold (p<0.001). 
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protein expression compared to parental cells (Figure 4-3b). Citrate synthase (CS) 
precedes isocitrate dehydrogenase (that generates aKG from isocitrate) in the 
TCA cycle, catalyzing a reaction that synthesizes citrate from OAA and acetyl-CoA. 
The dramatic increase in CS protein expression was not expected. However, 
studies have shown that increased concentrations of aKG drive the reductive 
carboxylation of aKG toward citrate and out of the mitochondria. This directional 
push is dependent on the ratio of aKG to citrate in the cell (Fendt et al., 2013b). 
Up-regulating the expression of CS and, consequently, the capacity of the cell to 
generate citrate, could function as a mechanism of resistance to high aKG 
concentrations, driving the TCA back in the oxidative direction and the electron 
transport chain.  
 
Proteomics pathway analysis reveals significantly altered pathways in aKG 
resistant cells. 
To identify the most significantly regulated pathways in aKG resistant cells 
emerging from the iTRAQ screen, we analyzed the proteomics data using 
Ingenuity Pathway Analysis (IPA), Reactome and Perseus pathway analysis tools. 
The consensus results of the three analyses indicated that pathways involving the 
initiation of protein translation were the most significantly altered in aKG resistant 
cells and represented a novel and potentially significant mechanism of aKG 
influenced cell physiology (Figure 4-3c, 4-3d).  
 
 
 
Figure 4-3. Pathway analyses of iTRAQ based proteomics in αKG resistant cells. 
List of most regulated proteins generated from a list positively identified peptides with no 
significance threshold (a). Western blot of Citrate Synthase from single cell clones 
derived from the αKG resistant population (b). Ingenuity Pathway Analysis from iTRAQ 
proteomics screen showing most significantly regulated pathways (c). Pathway 
networking analysis generated from Reactome software indicates strong network 
connectivity of translation initiation pathways (d). 
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Conclusions 
 
The proteomics screen provided valuable information about the impact of aKG on 
protein expression. On one hand the screen showed, as expected, that pathways 
such as oxidative phosphorylation, mitochondrial metabolism and the citric acid 
cycle were influenced by aKG. However, the screen also showed rather 
unexpectedly, that several protein translation pathways were altered in aKG 
resistant cells. One of the key regulators of protein translation, the mammalian 
target of rapamycin (mTOR), with its adaptor proteins that can sense amino acids 
such as leucine and directly signal to the protein translation apparatus the nutrient 
status of the cell, has often been implicated in cancer (Kim et al., 2002; Yuan et 
al., 2013).  It is tempting to speculate that aKG has a similar role to play in 
regulating protein translation, perhaps through a parallel mechanism. The 
regulation of protein translation by aKG treatment is the focus of ongoing studies 
in the lab. 
 
Our data also show significant regulation of One Carbon Metabolism (OCM) and 
DNA methylation pathways. These results were less surprising as the involvement 
of these pathways in 2-HG based oncogenesis has previously been reported 
(Koivunen et al., 2012; Koppenol et al., 2011). However, it was unclear how these 
pathways had adapted for survival in high aKG concentrations and we were 
interested in identifying the underlying mechanisms involved.  This was a novel 
perspective that could provide deeper insight into the pathways cancer cells 
become dependent on during metabolic and/or epigenetic stress. We focused on 
these pathways for the next phase of our investigation. 
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Chapter 5 
Targeting one carbon metabolism in αKG resistant cells 
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Introduction 
 
The previous chapter described a high-throughput proteomics screen that 
revealed signaling pathways significantly impacted by chronic treatment with 
alpha-ketoglutarate (αKG). Among those most significantly up-regulated was one 
carbon metabolism (OCM) that produces methyl donors for methytransferase 
reactions. The methylation and demethylation of histones and cytosines directly 
affects gene expression. The OCM is thus an important pathway for maintaining 
the epigenetic landscape of cancer cells. OCM has been therapeutically targeted 
in a broad spectrum of tumors for decades, with drugs such as methotrexate and 
5-fluorouracil that inhibit critical enzymes in this pathway reviewed in (Locasale, 
2013).  
 
We hypothesized that OCM was up-regulated in αKG resistant cells to counter the 
chronic demethylase activity induced by αKG ’s activation of Tet enzymes. 
Supporting this idea, a recent study indicated that colorectal and lung cancer cell 
lines, HCT116 and A549, harbor hyper-active OCM pathways (Maddocks et al., 
2016). Interestingly, both these cell lines remained almost completely refractive to 
the death promoting effects of αKG (Chapter 4, Figure 4-1). In the following 
section, we explore the possibility that a hyperactive OCM, which underlies the 
resistance to αKG, exposes a vulnerability in the resistant cells that could be 
therapeutically exploited.  
 
Results 
 
At the outset, we studied the expression pattern of OCM pathway components that 
emerged from the iTRAQ proteomics screen described in the previous chapter. 
We found significant up-regulation of individual enzymes that make up the one 
carbon metabolism pathway, including the cytosine methyl-transferase DNMT1 
(Figure 5-1a). We detected higher DNMT1 protein expression by Western blot in 
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nine different αKG resistant Jurkat clones compared to parental controls (Figure 
5-1b).  
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As alluded to above, αKG ’s activation of the Tet enzymes is predicted to cause 
changes in the epigenome. We hypothesized that OCM is enhanced as a 
counteractive measure aimed at restoring the methylation lost through the 
persistent Tet activity induced by αKG.  Thus, inhibiting OCM could render these 
cells susceptible to αKG exposure. The DNMT inhibitor, decitabine (DAC), 
currently used in the clinic to treat myelodysplastic syndrome, has been gaining 
recognition for its therapeutic potential against a broad spectrum of cancers 
(Cashen et al., 2010; Karahoca and Momparler, 2013). The in vitro efficacy 
reported for DAC is in the 500nM range (Karahoca and Momparler, 2013; Turcan 
et al., 2013). A Phase II clinical trial for acute myeloid leukemia recorded a 29% 
response rate, with responsive patients showing DAC plasma concentrations of 
greater than 1uM. DAC has side effects, such as fatigue, nausea, significant 
reduction in white blood cell counts and susceptibility to infection. We asked 
whether the αKG resistant Jurkat cells (T cell acute lymphoid leukemia) were 
dependent on DNMT1 activity for survival and, consequently, sensitive to lower 
concentrations of DAC in the presence of αKG. 
 
We found that αKG resistant Jurkat cells were susceptible to 1uM DAC in the 
absence of αKG (data not shown). However, two of the three αKG resistant clones 
tested were sensitive to concentrations of DAC as low as 10nm in the presence of 
4mM αKG, whereas a third clone (Clone 3) continued to be resistant (Figure 5-2a).  
These results support our hypothesis that up-regulation of DNMT1 and increased 
dependence on the OCM is one mechanism of resistance to the αKG promoted 
enhanced demethylation. Our iTRAQ proteomics screen revealed several 
pathways significantly regulated by αKG treatment, and the persistent lack of 
Figure 5-1. One carbon metabolism and the cytosine methylase DNMT1 are up-
regulated in αKG resistant cells. The one carbon metabolism pathway that generates 
methyl donors from glucose, folate and methionine for cytosine methylation by DNMT1. 
Up-regulation is shown in red, down-regulation is shown in green with numbers indicating 
fold change in regulation relative to parental cells (a). Western blot of DNMT1 in αKG 
resistant clones (b). 
	
	 52 
sensitivity exhibited by Clone 3 to αKG in the presence of DAC suggests that 
alternative mechanisms of αKG resistance might be in play in this clone. This will 
require further investigation in the future.   
 
We next looked at the colorectal (HCT116) and lung (A549) cancer cell lines, 
reported to show increased dependence on OCM (Maddocks et al., 2016), that we 
had determined were resistant to αKG (Figure 4-1). Again, both cell lines exhibited 
significant sensitivity to nanomolar concentrations of DAC in the presence of 4mM 
αKG (Figure 5-2b). We conclude from these data that αKG -induced persistent 
activation of the TET family of cytosine demethylases can lead to tumor 
suppressive changes to the epigenetic landscape, unless countered by 
constitutive activation of OCM or up-regulation of DNMT1 activity aimed at 
restoring the methylation patterns and repressive gene signatures of the cancer 
genome. This dependence on OCM exposes a vulnerability and opens a 
therapeutic window that can be exploited by OCM or DNMT1 inhibitors, such as 
DAC. 
 
Discussion 
 
The results described here identify one plausible mechanism for decreased 
sensitivity to increased intracellular concentrations of αKG observed in some 
cancers.  We had hypothesized that αKG could function as a tumor suppressor 
metabolite, based on the oncogenic properties of its antagonist 2HG (see Chapter 
1). The studies described in Chapters 4 and 5 support this characterization of αKG. 
Furthermore, our iTRAQ data offer a platform to begin identifying the fundamental 
mechanisms that may be harnessed for survival in the presence of this natural 
tumor suppressor. Although our current studies are limited to studying the effects 
of exogenously added cell permeable αKG, future studies will focus on evaluating 
DAC sensitivity in cells that are highly dependent on glutamine, such as Myc driven 
cancers. We are also interested in increasing intracellular αKG levels 
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pharmacologically by limiting oxidative phosphorylation with metformin (Wheaton 
et al., 2014) or low dose oligomycin (Sullivan et al., 2015). These data also support 
our hypothesis that cancer cells counter the growth suppressive effects of 
increased TET demethylase activity resulting from increased αKG concentrations 
Figure 5-2. Treatment with αKG sensitizes cancer cells to the DNMT1 inhibitor 
decitabine. Cell viability assayed by annexin-V/propidium iodide staining in αKG 
resistant clones (aKGR) derived from the population of cells used for the iTRAQ 
proteomics screen (a). Cell death in human lung (A549) and colorectal (HCT116) cancer 
cell lines assayed by cytotoxicity fluorescence (b). 
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by activating the pathway that provides methyl donors, including the methyl-
transferase itself.   
 
This would constitute a novel, 2-HG independent mechanism for repressing the 
downstream consequences of enhanced co-factor activity of αKG. Isocitrate 
dehydrogenase mutations have been reported primarily in glioblastomas and 
acute myeloid leukemias. However, many cancer cell types are dependent on 
increased glutamine consumption and are likely to have acquired adaptations to 
resist the effects of accumulation of this tumor suppressor metabolite and, as 
observed in clone 3 (Figure 5-2), these adaptations may not be restricted to OCM 
upregulation. 
 
⍺KG
TET DNMT1
One carbon 
metabolism
decitabine
Glutaminolysis
2-HG
⍺KG
Target gene: 
OFF
Target gene: 
ON
Figure 5-3. Model of the epigenetic methylation cycle. Increased cellular 
concentrations of αKG activate TET demethylases which, in turn remove inhibitory 
methyl groups (red circles) from the promoters of target genes and activate gene 
expression. Tet activity is inhibited by 2-HG in glioblastomas and myeloid 
leukemias. Up-regulation of the one carbon metabolism pathway and over-
expression of DNMT1 restores promoter methylation and represses target gene 
expression. Our results suggest decitabine may be an effective therapeutic in cells 
with increased intracellular αKG concentrations. 
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By revealing a dependence on one carbon metabolism and DNMT1, our studies 
expose a therapeutic window in a potentially broad panel of cancers. This 
increased dependence on DNMT1 is highly significant. Given its high plasma 
concentrations in responsive patients and its side effect profiles, the DNMT1 
inhibitor decitabine has yet to be adopted as an acceptable alternative to harsher 
chemotherapies or bone marrow transplants.	 However, our data show that 
decitabine is effective at killing αKG treated cells with concentrations two orders of 
magnitude lower than previously reported. These results could provide valuable 
insight into the efficacy of this drug in treating glutamine addicted tumors. Our 
studies also lay the foundation for the development of an αKG based treatment for 
cancer, specifically in combination with inhibitors of one carbon metabolism or 
methyltransferases. 	
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Chapter 6 
Discussion and future directions 
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Discussion and Future Directions 
 
The studies described here are centered around the metabolism of cancer. The 
profound metabolic changes that occur during proliferation can both be the cause 
and effect of tumorigenesis. Our studies bring significant new knowledge to both 
aspects of tumor metabolism that will inform the future of targeted therapies.  
 
We demonstrate that the Warburg effect, thought to be dependent solely on lactate 
dehydrogenase, utilizes malate dehydrogenase 1 (MDH1) as the cytosolic NAD 
regeneration mechanism. We report MDH1 is amplified more often than LDH and 
correlates with poor patient prognosis.  These are important findings as therapies 
targeting lactate dehydrogenase are entering clinical trials (Augoff et al., 2015; 
Billiard et al., 2013; Rani and Kumar, 2016).  We argue that MDH1 will also need 
to be targeted to effectively limit glucose consumption and the utilization of glucose 
carbon for biomass generation. Our results suggest MDH1 may even be a more 
‘efficient’ source for NAD in the cytosol than LDH.  We report that in the presence 
of MDH1, LDHA inhibition increased glucose consumption. Quantitatively it makes 
little sense to compare malate and lactate flux in the cell since lactate, as an 
endpoint metabolite tends to accumulate, unlike malate which is transient and acts 
as substrate for several other reactions.  This is an important distinction. Malate, 
in addition to functioning as an NAD regenerator, could also serve as a contributor 
to biomass as a substrate for the synthesis of non-essential amino acids or 
pyruvate. An independent published study found that pancreatic ductal carcinomas 
overexpress MDH1 to generate malate for malic enzyme which produces the 
NADPH required to quell the high oxidative stress of proliferation (Wang et al., 
2016).  In the cell types that we looked at, we found LDHA inhibition to have 
minimal effect on proliferation, in contrast to studies that had shown LDHA 
inhibition to be effective at inhibiting tumor cell growth (Billiard et al., 2013; Xie et 
al., 2014). Although our data conflict with these studies, there are studies 
suggesting lactate secretion and re-uptake may play a critical role in maintaining 
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de-differentiation by signaling in the NF-KB pathway (Vegran et al., 2011).  It has 
been suggested, moreover, that in animal models, increased lactate in the tumor 
microenvironment can stimulate endothelial cells to increase angiogenesis 
(Sonveaux et al., 2012).  It is important to note that our studies, rather than 
minimizing the value of lactate in cancer metabolism, are pointing to a novel 
supporting role for MDH1 providing, thereby, a more comprehensive view of 
Warburg metabolism. While the utility of lactate could wax and wane during 
tumorigenesis, increased glycolysis, and increased carbon appetite for biomass 
are constants during proliferation, underscoring the importance of targeting both 
dehydrogenases throughout tumor development.  
 
To date, attention has been focused largely on the TCA cycle mitochondrial 
enzyme, malate dehydrogenase 2 (MDH2), and little is known about the structure 
of MDH1.  Ongoing studies to address this lacuna include collaborative efforts with 
the Department of Medicinal Chemistry at the University of Minnesota to crystallize 
MDH1 and solve its structure, as well as computer modeling to create a “smart” 
library of compounds and set up a high throughput assay to screen for MDH1 
specific inhibitors.  
 
Our studies suggest that glutamine is a carbon source for the MDH1 reaction. 
Although, it is unlikely to be the only carbon source for this enzyme, we 
demonstrate that the availability of glutamine for the MDH1 reaction correlates with 
increased glycolysis. Indeed, we found dependence on glutamine for proliferation 
and glucose consumption is tied to MDH1 status again highlighting the importance 
of this reaction. To our knowledge, this is the first study showing how glutamine 
carbons are essential for supporting glycolysis. The linking of these two carbon 
sources through MDH1 reveals a metabolic vulnerability in cancer cells. 
 
Our studies also describe how cancer metabolism affects proliferation. The 
increased glutamine consumption by proliferating cells is often coupled with 
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increased intracellular concentrations of αKG. The αKG in turn acts on a variety of 
non-metabolic enzymes that regulate gene expression.  We offer evidence to 
support our hypothesis that αKG can function as a tumor suppressor and reveal 
novel pathways affected by αKG treatment. This is a newer concept in the field but 
is proving to be important in understanding how metabolism is woven into the 
physiology of the entire cell. The relaying of messages conveying nutrient 
availability is not by itself a novel idea. However, the messenger metabolites 
involved in relaying these signals and the mechanisms activated in response, to 
implement the required changes, are not fully understood. The realization that 2-
HG, the αKG antagonist, is a potent driver of oncogenesis has brought into focus 
the pathways affected by αKG. The increased intracellular concentrations of αKG 
precipitated by increased glutamine uptake, or perhaps through therapeutic 
intervention, are beginning to reveal vulnerabilities in tumor metabolism not 
previously appreciated. We utilized an innovative proteomics approach to parse 
out the most important pathways required for survival in cancer cells chronically 
exposed to αKG. The pathways revealed in our study open new and exciting 
avenues for future research. For example, the most significantly regulated 
pathways from both Ingenuity and Reactome pathway analyses involved initiation 
of protein translation. Further analyses of these pathways using Reactome, 
clustered these pathways in a manner that predicts mammalian target of 
rapamycin (mTOR) the master regulator of protein translation, as being 
fundamentally associated with αKG regulated protein translation. On its own, 
mTOR is one of the most investigated kinases in cancer metabolism today (Zoncu 
et al., 2011). Thus, the idea of mTOR as a sensor of input signals from nutrients is 
not new. Other groups have shown non-essential amino acids signal to mTOR 
through adaptor proteins that help initiate cellular protein translation or induce 
autophagy based on supply and demand (Kim et al., 2002; Kim et al., 2011). 
Surprisingly, αKG is yet to be implicated in any of these studies and future 
investigation in the lab will focus on this association. 
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Another major pathway affected by αKG treatment that emerged in our analysis 
was DNA methylation through one carbon metabolism. This pathway became the 
focus of our follow up studies for two reasons. First, αKG is a co-factor for the Tet 
family of enzymes that de-methylate cytosines and this activity is reported to be 
one of the crucial enzymatic mechanisms targeted by 2-HG during transformation 
(Xu et al., 2011). Thus, the one carbon metabolism pathway, constitutively 
activated for restoring methylation status, is an attractive target for therapeutic 
intervention in combination with αKG.  Second, one carbon metabolism has been 
the focus of intense study and chemotherapeutics for decades.  For example, 
methotrexate a DHFRL1 inhibitor, is a first line leukemia drug and 5-fluoruracil, 
used as therapeutic in many cancers is a semi-selective inhibitor of DNMT1. 
Although the epigenetics of a tumor cell change over time, it is becoming 
increasingly clear that acute changes to methylation can be catastrophic and 
induce cell death.  Thus, we may have identified a new strategy whereby clinically 
approved drugs targeting one carbon metabolism could be combined with αKG to 
potentiate tumor death at lower dosages, minimizing off target side effects and 
improving quality of life.  Indeed, combination of αKG treatment with the specific 
DNMT1 inhibitor decitabine reduced the amounts of drug required to promote 
death by at least one hundred-fold.  Our findings suggest that, in combination with 
αKG, the use of decitiabine, already available in the clinic for treating some 
leukemias could be expanded to treat other tumor types. 
 
Many more questions about the nature of αKG induced cytosine demethylation 
remain unanswered. Previous studies have reported treatment of pluripotent stem 
cells with αKG induces differentiation through global epigenetic changes (Figueroa 
et al., 2010; Losman et al., 2013; Lu et al., 2012). Importantly, αKG treatment has 
not been reported to demethylate cytosines with any specificity. Our hypothesis 
that αKG acts as a signaling metabolite to relay messages and influence 
physiology, encompasses the idea that αKG induced TET activity is directed at 
specific genes.  We have performed some preliminary studies using methyl DNA 
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immunoprecipitation (MeDIP) to further test this idea.  Preliminary studies strongly 
suggest that αKG induced promoter demethylation is specifically targeted (data 
not shown). These studies are ongoing and we anticipate identifying a library of 
promoters demethylated by αKG treatment in the future. This information will be 
valuable for developing therapeutic strategies centered around this natural tumor 
suppressor metabolite. 
 
In conclusion, these studies have made novel and significant advances in our 
understanding of metabolism in cancer, focusing not only on how proliferation 
affects metabolism but also on how metabolism affects proliferation. Our results 
inform a diverse audience of cancer researchers and are relevant to a large variety 
of tumors. These findings could lead to new cancer therapies that build upon 
current strategies based on how cancer cells utilize carbon. Our findings also lay 
the foundation for novel therapeutic approaches that can be applied to a broad 
field of proliferative diseases. 
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Chapter 7 
Materials and methods 
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Cell Culture   
Jurkat, HL60, DLD1, H522 and K562 (ATCC) cells were maintained in RPMI-1640 
medium supplemented with 10% FBS, 100 U/ml penicillin, 100ug/ml streptomycin, 
NEAA, and 4mM L-glutamine.  HEK293, A549, HCT116 and HeLa (ATCC) cells 
were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 
100ug/ml streptomycin. JPar and N5 cells have been previously described	
(Lowman).  MDH1 KO cells were a generous gift from Kivanc Birsoy and David 
Sabatini.	The LDHA inhibitor, GSK 2837808A (Tocris Bioscience, Bristol UK) was 
solubilized in DMSO, added to culture medium at the time of plating and 
maintained at 10uM throughout the experiment. Decitabine was purchased from 
Selleckchem (Houston, TX USA) dissolved in DMSO and used at indicated 
concentrations. 
 
Glucose and Lactate Measurements 
Concentration of glucose in the medium was measured via the EnzyChrom 
Glucose Assay Kit (BioAssay Systems, Hayward, CA USA) according to the 
manufacturer’s protocol, and then normalized to cell counts. Concentration of 
lactate in the medium was measured via the Lactate Assay kit (Sigma-Aldrich, St. 
Louis, MO USA) following filtration through a 10,000Kd MWCO spin filter. Lactate 
measurements were then normalized to cell number. 
 
Plasmid Constructs   
The MDH1 plasmid was a kind gift from S.M. Lee (Lee et al., 2009).  The MDH1 
insert was amplified from the source vector to carry a 5’ FLAG tag and cloned into 
pcDNA 3.1 and verified by sequencing.  The pcDNA 3.1 lacZ Myc/His construct 
was used as a vector control.  Transfections were carried out in 5E6 cells A549 
cells using 1ug of plasmid and 5ul of FuGENE HD (Promega, Madison, WI USA) 
reagent in 200ul of antibiotic free medium.  After a 15-minute incubation at ambient 
temperature, the DNA/FuGENE complex was added to a sub-confluent 10cm plate 
containing 10ml of antibiotic free medium. After 24 hours of transfection, medium 
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was replaced and supplemented with 1mg/ml of G418 (Geneticin) for one week.  
For Jurkat transfections, 10ug of plasmid was electroporated using a Neon 
Transfection System (Invitrogen, Carlsbad, CA, USA) into 10E6 cells in a 100ul 
Neon tip using 1350V at a pulse width of 10ms for 3 pulses. Cells were returned 
to antibiotic free medium for 24 hours. After 24 hours, medium was supplemented 
with G418 for 10 days.  Live cells were recovered using a Ficoll density gradient. 
 
Western Blot 
Cells were washed 1X with cold PBS, resuspended in Radio immunoprecipitation 
(RIPA) buffer supplemented with protease and phosphatase inhibitor cocktails.  
Lysates were incubated on ice for 10 min and spun at 10,000 rpm at 4°C in a 
microcentrifuge.  The supernatant was collected for further analysis.  After BCA 
protein assay, equal amounts of protein (10-50μg) were resolved by SDS-PAGE, 
transferred to nitrocellulose and probed with antibodies specific for Noxa (Santa 
Cruz, Santa Cruz, CA USA; SC-56169), beta actin (Santa Cruz; SC-69879), MDH1 
(Abcam, Cambridge, MA USA; Ab180152), LDHA (Cell Signaling Technology, 
Danvers, MA USA; #3582) Citrate synthase (Thermo Scientific, Rockford, IL; 
#GT2061) DNMT1 (Cell Signaling Technology; #5032) or the FLAG epitope 
(Sigma-Aldrich, St. Louis, MO USA; F7425). 
 
Seahorse Extracellular Flux Assay 
Seahorse base medium (Agilent, Santa Clara, CA USA) was supplemented with 
10mM glucose, 1mM sodium pyruvate and 4mM L-glutamine and adjusted to pH 
7.4 with NaOH. Cells were plated at 250,000 cells per well and adhered to the 
Seahorse 96 well culture plate using CellTak (Corning, Oneonta, NY USA).  
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were 
measured using the Seahorse XFe96 (Agilent, Santa Clara, CA USA). 
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Metabolic labeling experiments in cell culture 
Live, healthy cells were recovered by Ficoll density gradient centrifugation within 
24 hours prior to experiment.  At T0 10E6-20E6 cells per sample were pelleted and 
washed in glucose/glutamine free medium. For glucose labeling experiments, cells 
were resuspended at 1E6 cells/ml in complete glucose free medium supplemented 
with 10% dialyzed FBS, NEAA, and 4mM L-glutamine for 1 hour. After starvation, 
cells were supplemented with 10mM [13C] or [2H] labeled glucose for the time 
indicated in each experiment.  For glutamine labeling experiments cells were 
washed and then resuspended in complete glutamine free medium supplemented 
with 10% dialyzed FBS and 10mM glucose for 3-4 hours.  Following depravation, 
4mM [U-13C] glutamine was added to the medium and cells were incubated for 24 
hours.  Cells were then pelleted and washed 1X in ice cold PBS. Pellets were then 
resuspended in 100-200μl -20°C methanol, snap frozen and stored at -80C. Liquid 
chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS) were used for identification and quantification of labeled 
metabolites of all samples. [1,2-13C] glucose and [U-13C] glutamine was purchased 
from Cambridge Isotopes (Tewksbury, MA USA) and [4-2H] glucose was 
purchased from Omicron Biochemicals (South Bend, IN USA). 
 
Primary T cell experiments  
Human peripheral blood mononuclear cells (PBMCs) were obtained from a healthy 
donor via Memorial Blood Center (St. Paul, MN USA). PBMCs were purified from 
red blood cells using Histopaque. CD3+ T cells were isolated from PBMCs using 
the negative selection MACS magnetic separation system (Miltenyi Biotec, San 
Diego, CA USA) and allowed to recover in RPMI-1640 supplemented with 10% 
FBS, 100 U/ml penicillin, 100μg/ml streptomycin, NEAA, and 4mM L-glutamine 
overnight.  At 18 hours, live T cells were recovered by Ficoll density gradient 
centrifugation and allowed to rest for 4 hours before being washed in glucose-free 
medium and starved of glucose for 1 hour. For activation and metabolic labeling, 
T cells were moved to culture dishes coated with 5μg/ml anti-CD3 antibody 
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(Biolegend, San Diego, CA USA). 5ug/ml of anti-CD-28 antibody (Biolegend) was 
then added along with 10mM [4-2H] glucose.  Cells were harvested 18 hours later, 
resuspended in 150μl of cold -20°C methanol, snap frozen and stored at -80°C 
until required for metabolomics analysis. 
 
Central Carbon Metabolism sample preparation  
Microtubes containing cell pellets were removed from -80°C storage and 
maintained on wet ice throughout the processing steps. To initiate protein 
precipitation, 0.3 mL of a chilled mixture of methanol, chloroform and water (8:1:1) 
(EMD) was added to each sample, the mixture vortexed briefly, and allowed to 
incubate on ice for 10 mins.  Post-incubation, the vortex step was repeated, and 
samples centrifuged at 14,000 RPM, for 10 mins in 4°C.  Post-centrifugation, 100 
µL of supernatant was transferred to an autosampler vial for LC-MS analysis.  
From the remaining supernatant from each sample, a small aliquot was transferred 
to a new microtube to create a pooled sample for quality control purposes.  The 
remaining supernatant from each sample was transferred to an autosampler vial, 
and brought to dryness. To each sample, 50 µL of 20 mg/mL of a solution of 
methoxyamine hydrochloride in pyridine was added.  Samples were vortexed 
briefly and the samples incubated at 37°C for 90 mins.  Samples were removed 
from heating and allowed to cool to room temperature.  Addition of 50 µL of 
MTBSTFA with 1% tBDCMS (Regis Technologies, Morton Grove, IL USA) and 
samples were incubated at 70°C for one hour.  Samples were cooled and GC-MS 
was performed.  A series of calibration standards were prepared along with 
samples for quality control of instrument performance and chromatography for both 
LC and GC analysis.   
 
LC-MS analysis 
LC-MS analysis was performed on an Agilent system consisting of a 1260 UPLC 
module coupled with a 6520 Quadrupole-Time-of-flight (QTOF) mass 
spectrometer (Agilent Technologies, Santa Clara, CA USA) Metabolites were 
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separated on a 150x1mm Luna NH2 hydrophilic interaction chromatography 
column (Phenomenex, Torrance, CA USA) using 10 mM ammonium acetate in 
water, adjusted to pH 9.9 with ammonium hydroxide, as mobile phase A, and 
acetonitrile as mobile phase B.  The flow rate was 0.075 mL/min and the gradient 
was linear 20% to 100% A over 15 mins, followed by isocratic elution at 100% A 
for 5 minutes.  The system was returned to starting conditions (20% A) in 0.1 min 
and held there for 10 minutes to allow for column re-equilibration before injecting 
another sample. The mass spectrometer was operated in ESI- mode according to 
previously published conditions (Lorenz et al., 2011). 
 
GC-MS analysis 
GC-MS analysis was performed on an Agilent 69890N GC -5975 MS detector with 
the following parameters: a 1µL sample was injected splitlessly on an HP-5MS 
15m column (Agilent Technologies) with a helium gas flow rate of 1.4 mL/min.  The 
GC oven initial temperature was 60°C and was increased at 10°C per minute to 
300°C, and held at 300°C for 5 mins.  The inlet temperature was 250°C and the 
MS-source and quad temperatures were 230°C and 150°C respectively. 
 
Metabolite Data Analysis 
For LC-MS analysis, metabolite peaks (both molecular ion and stable isotopes) 
were identified by matching the retention time and mass (+/- 10 ppm) to authentic 
standards. For GC-MS, metabolite peaks (both molecular ion and stable isotopes) 
were identified by matching the retention time and mass (+/- 0.2 Da) to authentic 
standards. Metabolite masses (M-H for LC-MS, TBDMS derivative for GC-MS) are 
indicated in Supplementary Table 1, along with the qualifying ions used for the GC-
MS identification.  Isotope peaks (natural abundance and stable isotope labeling) 
were identified as increments of +1.0034 Da and +1 Da, respectively. Presence of 
stable isotope labeling above the natural abundance was verified by absence of 
the same MS peak in the unlabeled preparation of the same condition.  Peak areas 
were integrated using MassHunter Quantitative Analysis vB.07.00 (Agilent 
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Technologies) Peak areas were corrected for natural isotope abundance using an 
in-house written software package based on the method described previously 
(Lewis et al., 2014) and the residual isotope signal was reported. Data were 
normalized to cell protein content prior to analysis of metabolite fluxes for Central 
Carbon metabolites. 
 
Soft Agar Colony Assays 
Soft agar plates were prepared by mixing 3.2% low melt agarose with DMEM 
culture medium to yield 0.8% agarose at 38.5C. 1ml was added per well of a 6 well 
plate and allowed to solidify. 11,500 cells per ml were then mixed with 3.2% 
agarose to yield 0.48% agarose in DMEM culture medium and allowed to solidify. 
1ml of DMEM supplemented with 1mg/ml G418 was added to the top of the 
agarose. Each condition was plated in triplicate. Plates were incubated for 15 days. 
Colonies were stained with 0.005% crystal violet in PBS and 4% formaldehyde. 
Images were captured on an inverted microscope using QCapture software. Ten 
microscopic fields were captured and counted per condition. Colonies were 
counted using ImageJ software. 
 
Alpha-ketoglutarate cell viability assays 
Pure dimethyl-αKG was added to culture medium at 4mM. Cells were incubated 
for indicated times. For suspension cells, cultures were pelleted and washed in 
PBS. Cell pellets were then resuspended in 400ul of Annexin V-FITC (Biovision) 
and propidium iodide (0.5ug/ml) and analyzed on the LSRII (BDF Bioscience). 
Untreated cells were used to identify live populations and percentage of cells in 
this quadrant were applied to all conditions. For adherent cells, cell viability was 
measured via trypan blue exclusion using the Vicell (Beckman Coulter, 
Indianapolis, IN USA) by combining spent medium, PBS wash and trypsinized cells 
into a single tube for counting. Cytotoxcity was measured using the CytoTox Fluor 
kit per manufacturer’s instructions (Promega, Madison, WI USA). 
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Generation of alpha-ketoglutarate resistant cells 
Jurkat parental cells (ATCC) were grown to confluence and split into two 10ml 
cultures. One culture was treated with 4mM DM-αKG, the other was untreated. At 
days 2, 4, 7, 11, 15, 18, 22, 26 fresh medium and DM-αKG was added. At day 31, 
cells were collected and frozen down in liquid nitrogen. Bulk populations were used 
for proteomics experiments. Bulk cells were single cell cloned by limit dilution, 
grown to confluence and frozen in liquid nitrogen. 
 
iTRAQ proteomics of alpha-ketoglutarate resistant cells 
Parental Jurkat controls and bulk KG resistant cells were split into duplicate 
cultures and allowed to grow with or without 4mM DM-αKG for 2 days. Cells were 
pelleted and washed with ice cold 50ml PBS 5 times. The final pellet was dried by 
careful aspiration and stored at -80˚C. 
 
iTRAQ proteomics mass spectrometry 
We performed second dimension liquid chromatography (LC) online with an 
Orbitrap Velos mass spectrometer (MS) system (ThermoFisher, Waltham MA) as 
previously described (Lin-Moshier et al., 2013). Minor modifications to the capillary 
LC and MS parameters were: HCD activation time was 20 milliseconds; lock mass 
was off; dynamic exclusion settings were: repeat count = 1, exclusion list size = 
500, exclusion duration = 30 seconds, exclusion mass width (high and low) was 
15 ppm and early expiration was disabled. 
 
iTRAQ Proteomics Database Searching 
We converted the raw MS datafiles to MGF files with MS Convert from 
ProteoWizard Toolkit (PMID: 23051804). We used ProteinPilot™ v5.0 (Sciex, 
Framingham, MA), which uses the Paragon™ scoring algorithm (Shilov et al., 
2007) and the ProGroup™ protein grouping algorithm, for protein detection and 
relative quantification from peptide tandem MS data with MGF files as the input. 
We used the UniProt (http://www.uniprot.org/) human protein database from Dec 
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13, 2017 combined with the contaminants database 
(http://www.thegpm.org/cRAP/index.html) for a total of 92993 protein sequences 
as the reference database. ProteinPilot™ search parameters were: 8-plex peptide 
label sample type; cysteine methyl methanethiosulfonate; trypsin; instrument Orbi 
MS (1–3ppm) Orbi MS/MS; biological modifications ID focus; thorough search 
effort; detected protein threshold 0.05 (10%), competitive error margin 2.00 and 
false discovery rate analysis invoked (with reversed database). False discovery 
rate (FDR) calculations were performed in ProteinPilot™ with the concatenated 
forward and reversed protein sequence databases according to the method 
previously reported (Tang et al., 2008). ProteinPilot™ calculates an average 
protein relative fold change between two conditions along with a 95% confidence 
interval for the fold change and a p-value for a test of the null hypothesis unity (1:1 
ratio), which helps assess the statistical significance of a fold change.  
 
iTRAQ Proteomics Statistics and Pathway Analysis 
For a set of samples, ProteinPilot tests each subsequent sample against the first 
sample in the dataset (in this case, a control sample), and gives a ratio of protein 
expression between each subsequent sample and the first sample, as well as a p-
value for differential expression. Data were filtered to remove non-human, 
uncharacterized and cRAP proteins, as well as any proteins where any values 
were missing. To get a list of the proteins that were different between control and 
αKG samples, strict filtering criteria were used: Since values are all ratios of a 
sample's expression for a given protein compared to the first sample, proteins were 
only retained if the subsequent three control samples each had non-significant 
differences in expression, and the four αKG resistant samples had a significant 
difference. This limited the data to 230 proteins. A heatmap map of expression 
ratios was generated in R, using a value of 1 (it's ratio to itself) for the first sample 
(the sample which was the denominator in the expression ratios for all other 
samples). The R package ReactomePA (Yu and He, 2016)was used for pathway 
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analysis and to generate an enrichment map using the corresponding genes for 
the 230 significant proteins.  
An additional data analysis survey was performed by using MaxQuant. Following 
Maxquant converstion, data were filtered and analyzed in Perseus (Tyanova et al., 
2016), removing proteins only identified by site, reverse sequences and potential 
contaminants. Data were log2 transformed and further filtered to remove proteins 
with NA values in more than 4 samples. Two sample t-tests were conducted to 
determine significantly differentially expressed proteins. A Fisher's exact test was 
used to test for enrichment of GO terms, GSEA, KEGG and Reactome 
annotations.  
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